Acute and recurring pericarditis: More colchicine, less corticosteroids

Paul Farand, Francis Bonenfant, Emilie P Belley-Côté, Nicholas Tzouannis

INTRODUCTION

Pericarditis is a frequently encountered clinical entity. Studies have shown that pericarditis accounts for 5% of the final diagnoses among patients consulting in the emergency department for non-anginal chest pain\(^1\). Few studies have addressed the treatment of acute and recurring pericarditis and, until recently, recommendations were based on a few small studies. Moreover, one of the most complete publications on the subject, the “Guidelines on the Diagnosis and Management of Pericardial Diseases” from the European Society of Cardiology\(^2\), is based predominantly on expert opinion. However, in the past decade, several clinical studies have been published on pericarditis, mainly from Italian and Israeli researchers. A recent publication in Circulation\(^3\) and a publication from our group\(^4\) summarized these studies. It is important to note that some of these studies reinforce the current recommendations to use corticosteroids only in cases of treatment failure or intolerance to other treatments and support the use of colchicine, even for a first episode.

This article focuses on the treatment of pericarditis after a brief exploration of its pathophysiology, diagnosis and prognosis. Other pericardial pathologies such as constrictive pericarditis, chronic pericardial effusion and tamponade will not be discussed.

PATHOPHYSIOLOGY

The pericardial space is bordered by two layers: the fi-
Dec. 26, 2010

Acute and recurring pericarditis.

Inflammation of the pericardial layers leads to increasing exudation of fluid while decreasing the normal pericardial drainage by the lymphatic ducts. Thus, inflammation often leads to pericardial effusion. Although usually small, if sufficient, this volume of liquid can impinge on the filling of the right cardiac chambers, culminating with tamponade. Pericardial effusion occurring in a context of acute pericarditis is distinguished from chronic effusion by the fact that the effusion regresses when the inflammation resolves and the pericardium resumes its normal functions. On the other hand, chronic inflammation can lead to fibrosis and rigidity of the pericardium, as seen in constrictive pericarditis.

**PROGNOSIS**

Tamponade and constrictive pericarditis are the most serious complications of acute pericarditis. Tamponade can be life-threatening: the accumulated fluid causes compression of the cardiac chambers, preventing their filling. Prompt treatment is vital and consists in removal of the pericardial effusion, usually via pericardiocentesis. In contrast, in constrictive pericarditis, compression of the cardiac cavities results from a stiffened pericardium. Constrictive pericarditis presents with right heart failure and low cardiac output. The definitive treatment of this pathology is surgical removal of the pericardium, a high risk procedure. Fortunately, both of these complications rarely arise following acute or recurring pericarditis such as demonstrated in a review of several clinical studies on pericarditis. This review reports that 3% of patients with recurring pericarditis evolved towards tamponade and only 1 out of 296 patients developed constrictive pericarditis.

Several studies have tried to identify patients at high risk for the development of complications from an episode of acute pericarditis. Their goal was to determine the patients who would benefit from hospitalization for surveillance. High-risk features included: a pericardial effusion more than 20 mm, risk factors for hemorrhagic pericardial effusion (anticoagulation, neoplasia, accidental or iatrogenic thoracic trauma), temperature above 38°C, myopericarditis, pulsat paradoxus, evidence of systemic inflammation, subacute evolution (in contrast to acute) and, finally, patients with treatment failure. However, it is important to note that the majority of patients present none of these characteristics. Besides identifying the patients with a higher risk of complications, these characteristics can also help identifying those for whom a precise etiology is more likely to be discovered and who would benefit from a more extensive investigation.

A significant proportion of patients with acute pericarditis also present a certain degree of myocarditis, possibly because they share several common etiologies, in particular viral infections. Detection of these patients relies on an elevation of cardiac biomarkers (troponins, CK-MB) and a new left ventricular dysfunction as usually demonstrated by echocardiography. Besides providing hemodynamic support, if needed, guideline recommended therapy for non-ischemic left ventricular dysfunction is advised (β-blockers and angiotensin-converting enzyme inhibitors). Moreover, because of their possible harmful effects on myocarditis, non-steroidal anti-inflammatory drugs (NSAIDs) should be used with caution in perimyocarditis. It is recommended to use a lower dosage and to favour the use of acetylsalicylic acid. However, some causes of myocarditis require specific treatments, as described in a recent New England Journal of Medicine article.

The main concern in the evolution of acute pericarditis lies in the high rate of recurrences, which occur, on average, in 24% of patients, according to the biggest case-series available. This rate is approximately twice as frequent in recurring pericarditis.

---

**Figure 1** Transthoracic echocardiography. A: Parasternal long axis view showing a moderate pericardial effusion without compression of the cardiac cavities; B: Subcostal view showing a mild pericardial effusion without compression of the cardiac cavities.

---
**DIAGNOSIS**

Two out of four criteria are required to diagnose acute pericarditis. They include the presence of (1) a characteristic chest pain; (2) diffuse ST elevations; (3) a pericardial rub; and (4) a pericardial effusion\[^{[11]}\].

If suspected, the basic investigation, after history and physical examination, should include the following: an electrocardiogram, a chest X-ray, a transthoracic echocardiogram, cardiac biomarkers (troponins and creatine kinase), markers of inflammation [C-reactive protein (CRP) and sedimentation rate] as well as a complete blood count and a basic renal function profile. A more extensive workup is usually not required because the majority of pericarditis cases, seen in the emergency department in developed countries, are idiopathic. If a specific etiology is suspected, such as neoplasia, systemic disease, or tuberculosis, appropriate investigations should be performed\[^{[9]}\].

**TREATMENT**

Pericardial diseases are one of the few areas in cardiovascular medicine without multiple practice guidelines. The European Society of Cardiology is the only major organization that has established guidelines concerning pericardial diseases (2004). Moreover, these guidelines are mainly based on expert opinion because, until recently, few randomized controlled trials were available. In the past few years, several trials explored the subject, particularly regarding the role of colchicine and corticosteroids as treatments for acute and recurring pericarditis. This section will discuss these treatments in further detail.

**NSAIDs**

Although there is no large study on the use of anti-inflammatory drugs for the treatment of acute and recurring pericarditis, they remain the cornerstone of treatment. Clinical experience shows that in order to prevent treatment failure, both the dosage of NSAIDs and the duration of treatment must be adequate\[^{[8]}\]. Recommended dosages and tapering are presented in Table 1. Tapering of NSAIDs should not be attempted before complete resolution of symptoms. Also, the follow-up of inflammatory markers, such as CRP, should guide the tapering. It is recommended to wait for their normalization before every decrease in dosage\[^{[12]}\].

**Corticosteroids**

Corticosteroids are often used in acute and recurring pericarditis because of their ability to quickly induce a positive clinical response. However, recent recommendations limit their role because of the lack of clinical evidence showing medium and long-term benefit. Indeed, the use of corticosteroid therapy for recurring pericarditis is only supported by a retrospective study of 12 patients treated with high doses of prednisone\[^{[12]}\].

Recent data identified the use of corticosteroids as being a factor favoring the recurrence of pericarditis. High or low dosage of corticosteroids in the treatment of recurring pericarditis was evaluated in a retrospective study of 100 patients\[^{[3]}\]. The high dose group not only experienced more side effects, mainly osteoporosis, but also had more recurrences of pericarditis and hospitalizations. This increase in recurrences was also observed in two retrospective observational studies\[^{[14]}\].

These findings are reflected in the European recommendations which limit the use of corticosteroids to refractory and recurring pericarditis or in cases of intolerance, contraindication or failure of the usual treatments (NSAIDs and colchicine)\[^{[9]}\]. Patients receiving steroids for more than 3 mo should receive osteoporosis prophylaxis: calcium, vitamin D and bisphosphonates\[^{[16]}\]. The proposed corticosteroid doses are inferred from the experience acquired in the treatment of serositis such as in lupus and tuberculosis.
Acute and recurring pericarditis are frequently encountered clinical entities. Since severe complications such as tamponade and constrictive pericarditis occur in rare cases, the majority of patients suffering from acute pericarditis will have a benign clinical course. However, recurrence of pericarditis with its painful symptoms is much more frequent. On this matter, recent studies have demonstrated a benefit of colchicine in reducing the risk of recurrence of pericarditis, while also suggesting an increase in recurrence with the use of corticosteroids, the traditional first-line agent.

**REFERENCES**

1. **Imazio M**, Demichelis B, Parrini I, Cecchi E, Demarie D, Ghisio A, Belli R, Bobbio M, Trinchero R. Management, risk factors, and outcomes in recurrent pericarditis. *Am J Cardiol* 2005; 96: 736-739
2. **Maisch B**, Seferović PM, Ristic AD, Erbel R, Rienmüller R, Adler Y, Tomkowski WZ, Thieme G, Yacoub MH. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. *Eur Heart J* 2004; 25: 587-610
3. **Imazio M**, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. *Circulation* 2010; 121: 916-928
4. **Farand P**, Belley-Côte ÉP. Give a bigger place for colchicine and a smaller place for corticosteroids in the algorithm for the treatment of acute and recurring pericarditis. *MedActuel* 2010; 10: 1-5
5. **Imazio M**, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, Pomari F, Coda L, Berti L, Trinchero R. Indicators of poor prognosis of acute pericarditis. *Circulation* 2007; 115: 2739-2744
6. **Imazio M**, Trinchero R, Shabetai R. Pathogenesis, management, and prevention of recurrent pericarditis. *J Cardiovasc Med* (Hagerstown) 2007; 8: 404-410
7. **Spodick DH**. Risk prediction in pericarditis: who to keep in hospital? *Heart* 2008; 94: 398-399
8. **Imazio M**, Trinchero R. Myopericarditis: Etiology, management, and prognosis. *Int J Cardiol* 2008; 127: 17-26
9. **Cooper LT Jr**. Myocarditis. *N Engl J Med* 2009; 360: 1526-1538
10. **Soler-Soler J**, Sagristà-Sauleda J, Pernyanner-Miralda G. Relapsing pericarditis. *Heart* 2004; 90: 1364-1368
11. **Imazio M**, Brucato A, Trinchero R, Adler Y. Diagnosis and management of pericardial diseases. *Nat Rev Cardiol* 2009; 6: 743-751
12. **Marcolongo R**, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive therapy prevents recurrent pericarditis. *J Am Coll Cardiol* 1995; 26: 1276-1279
13. **Imazio M**, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, Maestroni S, Cecchi E, Berti R, Palmieri G, Trinchero R. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. *Circulation* 2008; 118: 667-671
14. **Azmoran G**, Konor-Morag N, Spodick DH, Brucato A, Guido J, Bayes-de-Luna A, Brambilla G, Finkelstein Y, Granell B, Bayes-Genis A, Schwammenthal E, Adler Y. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. *Eur Heart J* 2005; 26: 723-727
15. **Imazio M**, Brucato A, Trinchero R, Shabetai R, Spodick D, Adler Y. Corticosteroid therapy for pericarditis: a double-edged sword. *Nat Clin Pract Cardiovasc Med* 2008; 5: 118-119
16. **Homic J**, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M. Bisphosphonates for steroid induced osteoporosis. *Cochrane Database Syst Rev* 2000; CD001347
17. **Molad Y**. Update on colchicine and its mechanism of action.
18. Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, Ghisio A, Belli R, Trinchero R. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005; 165: 1987-1991

19. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammario M, Ghisio A, Belli R, Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112: 2012-2016

20. Imazio M, Cecchi E, Ierna S, Trinchero R. Investigation on Colchicine for Acute Pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design and rationale. J Cardiovasc Med (Hagerstown) 2007; 8: 613-617

21. Imazio M, Cecchi E, Ierna S, Trinchero R. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials--two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale. J Cardiovasc Med (Hagerstown) 2007; 8: 830-834

22. Brucato A, Brambilla G, Adler Y, Spodick DH. Recurrent pericarditis: therapy of refractory cases. Eur Heart J 2005; 26: 2600-2601

23. Pelliccia A, Corrado D, Bjorrestad HH, Panhuysen-Goedkoop N, Urhausen A, Carre F, Anastasakis A, Vanhees L, Arbustini E, Priori S. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil 2006; 13: 876-885